Alar Pharmaceuticals Overview
Get informed when a big investor buys or sells
+ Follow-77.06
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for 6785.TWO is -77.06. That is below the sector sector average of 24.62. Investors often review this figure alongside Alar Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, 6785.TWO currently prints -77.06 for P/E ratio, while the sector average sits near 24.62. That is roughly 412.9% below the sector mean. Large gaps often invite a closer look at Alar Pharmaceuticals's growth, margins, and balance sheet.
A P/E ratio of -77.06 for Alar Pharmaceuticals is not 'good' or 'bad' on its own. Compare it with the peer average (24.62) and with 6785.TWO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting 6785.TWO's P/E ratio (-77.06), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
